Os resultados do presente trabalho revelaram que o LEV (associado ou não à LIRA) mostrou potencial anti-kindling, enquanto a LIRA sozinha apenas retardou o estabelecimento do abrasamento, não sendo capaz de evitá-lo. Por outro lado, a LIRA foi capaz de prevenir os comportamentos ansiedade e depressão símiles e, na dose de 150 μg/kg, a disfunção cognitiva, provocados pelo abrasamento por PTZ, os quais não foram prevenidos com o tratamento com LEV. Por fim, quanto aos testes neuroquímicos, percebe-se que houve redução dos parâmetros de lesão oxidativa principalmente nos grupos tratados com a associação de LEV e LIRA, e na dosagem de BDNF, a LIRA (associada ou não ao LEV) levou a resultados aumentados significativamente em relação ao grupo PTZ.
Em conclusão, a LIRA (150 μg/kg) pode ser considerada promissora para tratamento de comorbidades associadas à epilepsia, visto que além de ter efeitos benéficos sobre as funções neurocomportamentais, ela não interfere no potencial anticonvulsivante do LEV e, em monoterapia, chega a retardar a evolução das convulsões. Sendo assim, sugere-se que a associação destes fármacos seria uma opção válida para o tratamento da epilepsia e suas comorbidades. Entretanto, mais estudos devem ser realizados neste âmbito, a fim de se comprovar os efeitos neuroprotetores de novos alvos terapêuticos e, assim, proporcionar uma melhor qualidade de vida aos pacientes epilépticos.
REFERÊNCIAS
ABBAS, T.; FAIVRE, E.; HOLSCHER, C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type β diabetes and Alzheimer’s disease. Behav Brain Res, v. 205, p. 265–71, 2009.
AGARWAL, N. B. et al. Effect of lamotrigine, oxcarbazepine and topiramate on cognitive functions and oxidative stress in PTZ-kindled mice. Seizure, v. 20, p. 257–262, 2011. AGRAWAL, N.; GOVENDER, S. Epilepsy and neuropsychiatric comorbidities. Advances in psychiatric treatment, v. 17, p. 44–53, 2011.
AGRAWAL, R. et al. Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetes. Biochimica et biophysica acta, v. 1842, n. 9, p. 1313-1323, 2014.
ALDENKAMP, A.; ARENDS, J. The relative influence of epileptic EEG discharges, short nonconvulsive seizures, and type of epilepsy on cognitive function. Epilepsia, v. 45, p. 54– 63, 2004.
ALDER, J. Early presynaptic and late postsynaptic components contribute independently to brain-derived neurotrophic factor-induced synaptic plasticity. J. Neurosci., v.25, p. 3080– 3085, 2005.
ARNAIZ, S.L. et al. Regional vulnerability to oxidative stress in a model of experimental epilepsy. Neurochem.Res., v. 23, p. 1477-1483, 1998.
BAGDY, G. et al. Serotonin and epilepsy. J Neurochem., v. 100, p. 857–873, 2007.
BAKKER, A. et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron., v. 74, p.467–474, 2012.
BARREIROS, A.L.B.S.; DAVID, J.M.; DAVID, J. P. Estresse oxidativo: relação entre geração de espécies reativas e defesa do organismo. Quim Nova., v.29, p.113-23, 2006. BASHKATOVA, V. et al. The influence of anticonvulsivante drugs on nitric oxide levels lipid peroxidation in the rat brain during penthylenetetrazole-induced epileptiformmodel seizures. Prog. Neuropycopharmacol. Biol. Psychiatry. v. 27, p. 487-492, 2003.
BAULAC, M. Historical data in the design and interpretation of trials with newly diagnosed patients. Epilepsy Res. v.68, n.1, p.77-81. 2006.
BECKMAN, J.S., KOPPENOL, W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol, v. 271, p. 1424-37, 1996.
BEGHI, M. et al. Learning disorders in epilepsy. Epilepsia, v. 47, p. 14–18, 2006.
BERRA, C. M.; MENCK, C. F. M.; DI MASCIO, P. Estresse oxidativo, lesões no genoma e sinalização no controle do ciclo celular. Química Nova, v.29, n. 6, p. 1340-1344, 2006.
BERTRAM, E. The relevance of kindling for epilepsy human. Epilepsia, v. 48, p. 65– 74, 2007.
BLUMENFELD, H. et al. Role of hippocampal sodium channel Nav1.6 in kindling epileptogenesis. Epilepsia, v. 50, p.44–55, 2009.
BRAGATTI, J. A. et al. Prevalence of psychiatric comorbidities in temporal lobe epilepsy in a Southern Brazilian population. Arq Neuropsiquiatr, v. 69, n. 2, p.159-165, 2011.
BRAGATTI, J. A. et al. Tryptophan hydroxylase 2 (TPH2) gene polymorphisms and psychiatric comorbidities in temporal lobe epilepsy. Epilepsy Behav, v. 32, p. 59-63, 2014. BRANDT, C. et al. Prophylactic treatment with levetiracetam after status epilepticus: Lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats.
Neuropharmacol., v. 53, p. 207–221, 2007.
BRIYAL, S.; GULATI, K.; GULATI, A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res. v. 1427, p. 23–34, 2012.
CAMPBELL, S.; MACQUEEN, G. The role of the hippocampus in the pathophysiology of major depression. J. Psychiatry Neurosci., v. 29, n. 6, p. 417-26, 2004.
CASTRÉN, E. Neurotrophins and psychiatric disorders. Handb Exp Pharmacol., v. 220, p.461–479, 2014.
CAUSING, C. G., et al. Synaptic innervation density is regulated by neuron-derived BDNF. Neuron, v. 18, p. 257–267, 1997.
Commission on Classification and Terminology of the International League Against Epilepsy (ILAE). Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia, v. 30, p. 389–399, 1989.
CUNHA, C.; BRAMBILLA, R.; THOMAS, K.L. A simple role for BDNF in learning and memory? Front. Mol. Neurosci, p. 1-14, 2010.
DARSALIA, V. et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes, v. 62 p. 1289–1296, 2013. DAWSON, T.M., SNYDER, S.H. Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J. Neurosci, v. 14, p. 5147–5159, 1994.
DEVASAGAYAM, T. P.; BOLOOR, K. K.; RAMASARMA, T. Methods for estimating lipid peroxidation: an analysis of merits and demerits. Indian J Biochem Biophys.,v. 40, n. 5, p. 300-308, 2003.
DEVINSKY, O. Psychiatric comorbidity in patients with epilepsy: implications for diagnosis and treatment. Epilepsy and Behavior, v. 4, p. 2–10, 2003.
DHIR, A.; NAIDU, P. S.; KULKARNI, S. K. Neuroprotective effect of nimesulide, a
preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure, v. 16, p. 691–697, 2007.
DODRILL, C.B., 2004. Neuropsychological effects of seizures. Epilepsy Behav. v. 5, p. S21– S24.
DREVETS, W.C.; PRICE, J.L.; FUREY. M.L.Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct., v. 213, n. 1–2, p. 93-118, 2008.
DRUCKER, D. J. The biology of incretin hormones.Cell metabolism v. 3, p. 153-165, 2006. DURING, M. J. et al. Glucagon-like peptide-1 receptor is involved in learning and
neuroprotection. Nat Med., v. 9, p. 1173–1179, 2003.
EL-ABHAR, H. S.; EL GAWAD, H.M.A. Modulation of cortical nitric oxide synthase, glutamate, and redox state by nifedipine and taurine in PTZ-kindled mice. Epilepsia, v. 44, p. 276–28, 2003.
ELENA, A. M. et al. Levetiracetam Prevents Kindling-Induced Asymmetric Accumulation of Hippocampal 7S SNARE Complexes. Epilepsia, v. 49, n. 10, p. 1749–1758, 2008.
ELKINSON, S.; KEATING, G.M.. Lixisenatide: first global approval. Drugs, v. 73, p. 383– 391, 2013.
ENGEL JR, J. Concepts of epilepsy. Epilepsia, v. 36, n. 1, p. 23-29, 1995.
ENNACEUR, A.; DELACOUR, J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behavioural brain research, v. 31, n. 1, p. 47–59, 1988.
ERAKOVIC, V. Altered activities of rat brain metabolic enzymes by pentylenetetrazol kindling and pentylenetetrazol-induced seizures. Epilepsy Res.,v. 43, n. 2, p. 165-173, 2001.
FEINSTEIN, A. R. The pretherapeutic classification of comorbidity in chronic disease. J Chronic Dis, n. 2, p. 455–468, 1970.
FERREIRA, A. L. A.; MATSUBARA, L. S. Radicais livres: conceitos, doenças relacionadas, sistema de defesa e estresse oxidative. Rev Ass Med Brasil, v. 43, p. 61- 8, 1997.
FERRIERO, D. M. Protecting neurons. Epilepsia, v. 46, n. 7, p. 45–51, 2005. FISHER, R. S. et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia, v. 55, n. 4, p. 475-482, 2014.
FISHER, R. S. Redefining epilepsy. Curr Opin Neurol, v. 28, n. 2, p. 130-135, 2015. FRICK, K.M. et al. Reference memory, anxiety and estrous cyclicity in C57BL/6NIA mice are affected by age and sex. Neuroscience, v. 95, p. 293–307, 2000.
FUCHS, F.D.; WANNMACHER, L.; FERREIRA, M.B.C. Farmacologia clínica. Rio de Janeiro: Guanabara Koogan, cap. 43, p. 536-553, 2004.
GAITATZIS, A.; TRIMBLE, M. R.; SANDER, J. W. The psychiatric comorbidity of epilepsy. Acta Neurol Scand, v. 110, p. 207–220, 2004.
GAITATZIS, A.; TRIMBLE, M. R.; SANDER, J. W. The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia, v. 53, p. 1282–1293, 2012.
GOLDENSOHN, E. S.; PORTER, R. J.; SCHWARTZKROIN, P. A. The American Epilepsy Society: an historic perspective on 50 years of advances in research. Epilepsia, v. 38, p. 124–50, 1997.
GOMES, M. M. History of epilepsy: a epistemologic point of view. J. Epilepsy Clin. Neurophysiol, v. 12, n.3, p. 161-167, 2006.
GOWER, A. J.; FALTER, U.; LAMBERTY, Y. Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat. Eur J Pharmacol. v. 481, n. 1, p. 67–74. 2003.
GREEN, L. et al. Preference reversal and self- control: choice as a function of reward amount and delay. Behav. Anal. Lett., v.1, p. 43–51, 1981.
GREIG N. H. et al. Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimers Dement, v. 10, p. 62–75, 2014.
GUPTA, Y.; KUMAR, M.V.; SRIVASTAVA, A. Effect of Centella asiatica on
pentylenetetrazole-induced kindling, cognition and oxidative stress in rats. Pharmacol Biochem Behav. v. 74, p. 579–585, 2003.
HALLIWELL, B. Biochemistry of oxidative stress. Biochem Soc Trans., v.35, p. 1147-50, 2007.
HALLIWELL, B.; GUTTERIDGE, J. Free Radicals in Biology and Medicine. 4 ed. Oxford: Oxford University Press, 2007.
HAMILTON, A.; HOLSCHER, C. Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. Neuroreport, v. 20, p. 1161–1166, 2009.
HANNESSON, D.K., CORCORAN, M.E. The mnemonic effects of kindling. Neuroscience and Biobehavioral Reviews, v. 24, p. 725-751, 2000.
HE, X. P. et al., Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model. Neuron., v. 43, n. 1, p. 31-42, 2004.
HELDT, S. A. et al. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry, v. 12, p. 656–670, 2007. HELMSTAEDTER, C.; KURTHEN, M. Memory and epilepsy: characteristics, course, and
influence of drugs and surgery. Curr. Opin. Neurol. v. 14, p. 211–216, 2001.
HENSHALL, D. C.; SIMON, R. P. Epilepsy and apoptosis pathways. J. Cereb. Blood Flow Metab. v. 25, n. 12, p. 1557–1572, 2005.
HERSHKO C. Mechanism of iron toxicity and its possible role in red cell membrane damage. Semin Hematol., v.26, p. 277-85, 1989.
HOLSCHER, C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. Alzheimers Dement., v. 10, p. S47–S54, 2014.
HOPKINS, A.; SHORVON, S. Computed tomography in first uncomplicated generalized seizure. Is grossly oversold. BMJ, v. 10, p. 1007-1008, 1995.
HUONG, N. T. T. et al. In vitro antioxidant activity of Vietnamese ginseng saponin and its components. Biological and Pharmaceutical Bulletin, v. 21, n. 9, p. 978–981, 1998. IDORN, T. et al. Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease. Nephrol Dial Transplant., v. 29, n. 1, p. 119-27, 2014. Indian Epilepsy Society. Guidelines for Management of Epilepsy in India (GEMIND) 2008. Disponível em: <http://www.epilepsyindia.org/ies/GUIDELINES/Gemind_Combine.pdf > Acesso em 20 mar 2017.
ITZHAK, Y., MARTIN, J.L. Cocaine-induced kindling is associated with elevated NMDA receptor binding in discrete mouse brain regions. Neuropharmacology, v.39 p 32-9, 2000. JACOBY, A.; SNAPE, D.; BAKER, G. A. Epilepsy and social identity: the stigma of a chronic neurological disorder. Lancet Neurol. v. 4, p. 171–178, 2005.
JAIN, S. et al. Anticonvulsant and antioxidant actions of trimetazidine in pentylenetetrazole- induced kindling model in mice. Naunyn Schmiedebergs Arch Pharmacol, v. 383, p. 385- 92, 2011.
JUNG, K. H. et al. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther., v. 322, n. 3, p. 1051-1058, 2007.
KAMBLE, M. et al. Neurobehavioral effects of liraglutide and sitagliptin in experimental models. European Journal of Pharmacology. v. 774, p. 64–70, 2016.
KAMINSKI, R.M. et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology, v. 54, n. 4, p. 715-720, 2008.
KANEKO, K. et al. Consequences of nitric oxide generation in epileptic-seizure rodent models as studied by in vivo EPR. Magn. Redon. Med., v. 48, n. 6, p. 1051-1056, 2002. KANNER, A. M. Depression in epilepsy: prevalence, clinical semiology, pathogenic
mechanisms, and treatment. Biological Psychiatry, v. 54, p. 388–398, 2003.
KANNER, A.M.; MAZARATI, A.; KOEPP, M. Biomarkers of epileptogenesis: psychiatric comorbidities. Neurotherapeutics, v. 11, n.2, p. 358-372, 2014.
KAUR, H. et al. Anti-amnesic effect of Ficus religiosa in scopolamine-induced anterograde and retrograde amnesia. Pharm. Biol., v. 48, p. 234–240, 2010.
KATOH-SEMBA, R. et al. Brain-derived neurotrophic factor, nerve growth and neurotrophin- 3 selected regions of the rat brain following kainic acid-induced seizure activity. Neurosci. Res., v. 35, p.19–29, 1999.
KATZUNG, B. G. Farmacologia básica e clínica. 12. ed. Porto Alegre: AMGH, 2014. KHURANA, N. et al. PASS assisted prediction and pharmacological evaluation of novel nicotinic analogues for nootropic activity in mice. Eur. J. Pharmacol., v. 662, p. 22–30, 2011.
KINZIG, K.P. et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors, J Neurosci. v. 23, p. 6163–6170, 2003. KLITGAARD, H. et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol., v. 353, n. 2–3, 191-206, 1998.
KLITGAARD, H.; PITKANEN, A. Antiepileptogenesis, neuroprotection, and disease
modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord, v. 5, n. 1, p. 9–16, 2003.
KOMSUOGLU, C.I. et al. Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes. Med Sci Monit Basic Res. v. 20, p. 112–117, 2014.
KOSHAL, P.; KUMAR, P. Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice. Mol Cell Biochem v. 415, p. 77–87, 2016.
KRAUS, J.E. Sensitization Phenomena in Psychiatric Illness: Lessons from the Kindling Model. The Journal of Neuropsychiatry and Clinical Neurosciences, v. 12, p. 328–343, 2000.
KULAK, A. et al. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antioxid Redox Signal., v. 18, n. 12, p. 1428-1443, 2013.
KUMARI, A. et al. Social isolation mediated anxiety like behavior is associated with enhanced expression and regulation of BDNF in the female mouse brain. Physiol Behav., p.461–479 v. 158, 2016.
conflict test in the rat. Eur J Pharmacol., v. 469, n. 1–3, p. 97–102, 2003.
LEE, B. et al. The CREB/CRE transcriptional pathway: protection against oxidative stress- mediated neuronal cell death. J Neurochem, v. 108, p. 1251–1265, 2009.
LEE, C.H. et al. Ischemia-induced changes in glucagon-like peptide-1 receptor and
neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J. Neurosci. Res. v. 89, p. 1103–1113, 2011.
LHATOO, S. D.; SANDER, J. W. A. S. The epidemiology of epilepsy and learning disabilities. Epilepsia, v. 42, n.1, p. 6–9, 2001.
LI, L. M., SANDER, J. W. National demonstration project on epilepsy in Brazil. Arq Neuropsiquiatr., v. 61, n. 1, 153-156, 2003.
LI, Y. et al. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J Neurochem. v.135, n. 6, p.1203–1217, 2015.
LIANG, L. P.; HO, Y. S.; PANTEL, M. Mitochondrial superoxide production in kainateinduced hippocampal damage. Neuroscience, v. 101, n. 3, p. 563-570, 2000.
LIU, D.S. et al. Lamina- specific changes in hippocampal GABA(A)/cBZR and mossy fibre sprouting during and following amygdala kindling in the rat. Neurobiol Dis, v. 35, p.337– 347, 2009.
LIU, F. et al. The link between angiotensin II-mediated anxiety and mood disorders with NADPH oxidase-induced oxidative stress. Int J Physiol Pathophysiol Pharmacol., v. 4, n. 1, p. 28-35, 2012.
LÖSCHER W. New visions in the pharmacology of anticonvulsion. European Journal of Pharmacology. v.342, p.1.13, 1998.
LÖSCHER, W.; HÖNACK, D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol., v. 232, n. 2–3, p. 147-158, 1993.
LOSCHER, W.; HONACK, D.; RUNDFELDT, C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther., v. 284, p. 474–9, 1998.
LOVSHIN, J.A.; DRUCKER, D.J.. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol., v. 5 p. 262–269, 2009.
LYNCH, B. A. et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Nat Acad Sci., v. 101, p. 9861–9866. 2004.
MA, M. et al. Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid
antidepressant effect in social defeat stress model: Role of BDNF TrkB signaling. Sci. Rep., v. 6, p. 1-23, 2016.
MAES, M. et al. Depression’s multiple comorbidities explained by (neuro) inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett., v.32, n.1, p. 7-24, 2011. MAGALHÃES, P. V. et al. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J. Affect. Disord., v. 129, n. 1–3, p. 317–320, 2011.
MAGIORKINIS, E. et al. Highlights in the history of epilepsy: the last 200 years. Epilepsy, v. 2014, 2014.
MAROSI, K.; MATTSON, M. P. BDNF Mediates Adaptive Brain and Body Responses to Energetic Challenges. Trends in endocrinology and metabolism: TEM., v. 25, n. 2, p. 89- 98, 2014.
MASIA, S. L.; DEVINSKY, O. Epilepsy and behavior: A brief history. Epilepsy Behav. v. 1, n. 1, p. 27-36, 2000.
MAZHAR, F.; MALHI, S. M.; SIMJEE, S. U. Comparative studies on the effects of clinically used anticonvulsants on the oxidative stress biomarkers in pentylenetetrazole-induced
kindling model of epileptogenesis in mice. J Basic Clin Physiol Pharmacol., v. 28, n.1, p. 31-42, 2017.
MEHLA, J. et al. Protective effect of curcumin against seizures and cognitive impairment in a pentylenetetrazole-kindled epileptic rat model. Life Sciences. v.87, p. 596–603, 2010.
MELO, T. G.. et al - Antidepressants differentially modify the extinction of an aversive memory task in female rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry. v. 37, n. 1, p. 33-40, 2012.
MISHRA, A.; GOEL, R.K. Age dependent learning and memory deficit in Pentylenetetrazol kindled mice. Eur J Pharmacol. v. 674 p. 315-20, 2012.
MITRE, M.; MARIGA, A.; CHAO, M.V. Neurotrophin signalling: novel insights into mechanisms and pathophysiology. Clin. Sci., v. 131, p. 13-23, 2017.
MULA, M.; TRIMBLE, M. R.; SANDER, J.W.A.S. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure, v. 13, p. 55–57, 2004. NANDAM, L.S.; JHAVERI, D.; BARTLETT, P. 5-HT7, neurogenesis and antidepressants: a promising therapeutic axis for treating depression. Clin Exp Pharmacol Physiol, v. 34, p. 546-551, 2007.
OHNO, Y. et al. Antiepileptogenic and anticonvulsive actions of levetiracetam in a pentylenetetrazole kindling model. Epilepsy Res., v. 89, n. 2–3, p. 360-364, 2010. OLIVEIRA, A. A. et al. Effects of levetiracetam in lipid peroxidation level, nitrite–nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures. Cellular and Molecular Neurobiology, v. 27, n. 3, p. 395–406, 2007.
OSUCH, E.A. et al. Regional cerebral metabolism associated with anxiety symptoms in affective disorder patients. Biol. Psychiatry, v. 48, n. 10, p. 1020-3, 2000.
PALLERIA, C. et al. Liraglutide prevents cognitive decline in a rat model of streptozotocin- induced diabetes independently from its peripheral metabolic effects. Behavioural Brain Research. v. 321. n.157–169, 2017.
PAPP, L. A. et al. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry., v. 67, n. 10, p. 1573–1576, 2006.
PELLOW, S.; FILE, S.E., Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. v. 24, p. 525–529, 1986.
PERRY, T. et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther., v. 302, p. 881–888, 2002a.
PERRY, T. et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. v. 300, p. 958–966, 2002b.
PERRY, T. et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol., v. 203, p. 293–301, 2007.
PINEL, J.P.J., ROVNER, L.I. Experimental Epileptogenesis - Kindling-Induced Epilepsy in Rats: Experimental Neurology, v. 58, p. 190-202, 1978.
PITTENGER, C.; DUMAN, R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacol Rev., v. 33, p. 88-109, 2008.
PORSOLT, R. D.; ANTON, G.; BLAVET, N. et al. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol, v.47, 1978, p. 379-391.
POST, R.M. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neuroscience and Biobehavioral Reviews, v. 31, p. 858–87, 2007.
POURMOTABBED, A. et al. Effect of prenatal pentylenetetrazol-induced kindling on learning and memory of male offspring. Neuroscience, v. 172, p. 205–211, 2011.
PRASAD, A. S. et al. Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. Am J Clin Nutr., v. 85, n. 3, p. 837-44, 2007.
PRUT, L.; BELZUNG, C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviours: a review. European Journal of Pharmacology. v. 463, n.1-3, p.3- 33, 2003.
QUESSEVEUR, G., et al. BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic like activities. Transl. Psychiatry., v. 3, p. e53, 2013.
QUINTANS-JÚNIOR, L. J. Modelos animais para avaliação de drogas anticonvulsivantes: uma revisão. Rev. Bras. Farm., v.88, p.163-166, 2007.
RACHMANY, L. et al. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age. v.35, n. 5, p. 1621-1636, 2013.
RACINE, R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Eletroenceph. Clin. Neurophysiol, v. 32, p. 281-294, 1972.
RADENOVIC, L. et al. 7-Nitroindazole reduces nitrite concentration in rat brain after intrahippocampal kainate-induced seizure. Comp. Biochem. Physiol.C Toxicol.
Pharmacol., v.135, v. 4, p. 443-450, 2003.
RADI, R. et al. Peroxynitrite oxidation of sulfhydryls: the citotoxic potential of superoxide and nitric oxide. J. Biol. Chem, v. 266, p. 4244–4250, 1991.
RANTANEN, K. et al. Social competence of preschool children with epilepsy. Epilepsy Behav. v. 14, p. 338–343, 2009.
RAUCA, C. et al. The role of superoxide dismutase and alpha-tocopherol in the development of seizures and kindling induced by pentylenetetrazol — influence of the radical scavenger alpha-phenyl-N-tert-butyl nitrone. Brain Res., v. 1009, p. 203–212, 2004.
ROBINS, A.; PATEL, M.; AZIM, A. A case of physical and mental adverse drug reactions associated with levetiracetam in post-stroke epilepsy. J Am Geriatr Soc.,v. 60, p. 159–60, 2012.
ROBINSON, J. E. et al. Levetiracetam has opposite effects on alcohol- and cocaine-related behaviors in C57BL/6J mice. Neuropsychopharmacol., v. 38, p. 1322–1333. 2013.
RUSSO, E. et al. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia. v. 52, n.7, p. 1341-50, 2011.
SANCHEZ, P. E. et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. v. 109, p. E2895–2903, 2012.
SANDI, C.; PINELO-NAVA, M.T. Stress and memory: behavioral effects and neurobiological mechanisms. Neural Plast., v. 1, p. 1-20, 2007.
SARANGI, S.C. et al. Effect of Lamotrigine, Levetiracetam & Topiramate on
Neurobehavioural Parameters & Oxidative Stress in Comparison with Valproate in Rats. The Indian Journal of Medical Research, v.144, n.1, p. 104–111, 2016.
SATO, K. et al. Neuroprotective effects of liraglutide for stroke model of rats. Int. J. Mol. Sci. v. 14, p. 21513–21524, 2013.
SATO, K. et al. Regional increases in brain-derived neurotrophic factor and nerve growth factor mRNAs during amygdaloid kindling, but not in acidic and basist growth factor mRNAs. Epilepsia, v. 37, p. 6–14, 1996.
SCHENKEL, L. C. et al. Serotonin gene polymorphisms and psychiatry comorbidities in temporal lobe epilepsy. Epilepsy Res, v. 99, n. 3, p. 260-266, 2012.
SCHMIDT, D.; SCHACHTER, S. C. Drug treatment of epilepsy in adults. BMJ, v. 348, p. g254, 2014.
SEDLAK, J.; LINDSAY, R. H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal. Biochem., v. 25, n. 1, p. 192–205, 1968. SEHAR, N. et al. Atorvastatin prevents development of kindling by modulating hippocampal levels of dopamine, glutamate, and GABA in mice. Epilepsy Behav, v. 42, p. 48–53, 2015. SHARMA, A.N. Glucagon‐like peptide‐1 (GLP‐1) receptor agonist prevents development of tolerance to anti‐anxiety effect of ethanol and withdrawal‐induced anxiety in rats. Metab Brain Dis., 2014.
SHARMA, M.; JALEWA, J.; HOLSCHER; C. Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J. Neurochem., v. 128, p. 459–471, 2013.
SILLS, G. J. et al. Pharmacodynamic interaction studies with topiramate in the
pentylenetetrazol and maximal electroshock seizure models. Seizure, v. 13, n. 5, p.287-95, 2004.
SIMON, N. M. et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry., v. 65, n. 9, p. 1219–1222, 2004.
SINGH, T.; KAUR, T.; GOEL, R. K. Adjuvant quercetin therapy for combined treatment of epilepsy and comorbid depression. Neurochem Int., v. 104, p. 27-33, 2017.
SMITH, M; WILCOX, K.S.; WHITE, H.S. Discovery of antiepileptic drugs. Neurotherapeutics: The Journal of the American Society for Experimental, NeuroTherapeutics, v.4, p.12-17, 2007.
STAFSTROM, C.E., SUTULA, T.P. Models of epilepsy in the developing and adult brain: Implications for neuroprotection. Epilepsy & Behavior, v.7, p.18–24, 2005.
SUNDQVIST, A. Epilepsy: a clinical diagnostic overview. Eur J Pain. v. 6, p. 21-25, 2002.